drugset

drugset / Trial / NCT05358886

A Study of BPN14770 in Male Adults (Aged 18 to 45) With Fragile X Syndrome

NCT05358886 ↗

Phase 3 Completed 171 enrolled Tetra Discovery Partners

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study of BPN14770 in Male Adults (Aged 18 to 45) with Fragile X Syndrome

Timeline

Start: 2022-11-01
Primary completion: 2025-07-18
Completion: 2025-07-18

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	zatolmilast	Small molecule	25 mg	—

Indications